These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36471595)

  • 1. [Low protein diet with essential amino acids ketoanalogues combination can affect serum FGF-23 and Klotho levels in chronic kidney disease 3b-4 stages patients: randomized pilot study].
    Milovanova LY; Kozlovskaya Lysenko LV; Androsova TV; Lebedeva MV; Taranova MV; Milovanova SY; Kondratyeva TB; Zubacheva DO; Tchebotareva NV; Kozlov VV; Kuchieva AM; Li OA; Reshetnikov VA
    Ter Arkh; 2019 Jun; 91(6):47-56. PubMed ID: 36471595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.
    Milovanova L; Fomin V; Moiseev S; Taranova M; Milovanov Y; Lysenko Kozlovskaya L; Kozlov V; Kozevnikova E; Milovanova S; Lebedeva M; Reshetnikov V
    Clin Exp Nephrol; 2018 Dec; 22(6):1351-1359. PubMed ID: 29948444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in patients with chronic kidney disease].
    Taranova MV; Milovanova LY; Kozlovskaya Lysenko LV; Milovanova SY; Androsova TV; Zubacheva DO; Lebedeva MV; Dobrosmyslov IA; Kozlov VV; Kuchieva AM; Li OA; Reshetnikov VA
    Ter Arkh; 2019 Jun; 91(6):85-92. PubMed ID: 36471601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of keto/amino acids and a low-protein diet on the nutritional status of patients with Stages 3B-4 chronic kidney disease].
    Milovanova SY; Milovanov YS; Taranova MV; Dobrosmyslov IA
    Ter Arkh; 2017; 89(6):30-33. PubMed ID: 28745686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.
    Milovanova LY; Taranova MV; Milovanova SY; Kozlovskaya Lysenko LV; Pasechnik AI; Kozlov VV; Beketov VD; Volkov AV; Ratanov M
    Int Urol Nephrol; 2022 Jul; 54(7):1613-1621. PubMed ID: 34718928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
    Milovanova LY; Dobrosmyslov IA; Milovanov YS; Taranova MV; Kozlov VV; Milovanova SY; Kozevnikova EI
    Ter Arkh; 2018 Jun; 90(6):48-54. PubMed ID: 30701904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soy Protein as a Part of a Low-protein Diet is a New Direction in Cardio- and Nephroprotection in Patients With 3b-4 Stages of Chronic kidney Disease.
    Milovanova LY; Volkov AV; Milovanova SY; Taranova MV; Nezhdanov KS
    J Ren Nutr; 2023 May; 33(3):435-442. PubMed ID: 36379387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Soy protein as part of a low-protein diet is a new direction in cardio- and nephroprotection in patients with 3B-4 stages of chronic kidney disease: prospective, randomized, controlled clinical study].
    Milovanova LY; Taranova MV; Volkov AV; Milovanova SY; Beketov VD
    Ter Arkh; 2022 Aug; 94(6):756-762. PubMed ID: 36286853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of vitamin D receptor activators on serum Klotho levels in 3b-4 stages chronic кidney disease patients: a prospective randomized study].
    Milovanova LY; Beketov VD; Milovanova SY; Taranova MV; Kozlov VV; Pasechnik AI; Reshetnikov VA; Androsova TV; Kalashnikov MV
    Ter Arkh; 2021 Jun; 93(6):679-684. PubMed ID: 36286834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2-5D].
    Milovanova LY; Lysenko Kozlovskaya LV; Milovanova SY; Taranova MV; Kozlov VV; Reshetnikov VA; Lebedeva MV; Androsova TV; Zubacheva DO; Chebotareva NV
    Ter Arkh; 2020 Jul; 92(6):37-45. PubMed ID: 33346491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
    Milovanova LY; Mukhin NA; Kozlovskaya LV; Milovanov YS; Kiyakbaev GG; Rogova IV; Lebedeva MV; Androsova TV; Milovanova SY; Gil AY; Taranova MV
    Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc Supplementation Trial in Pediatric Chronic Kidney Disease: Effects on Circulating FGF-23 and Klotho.
    Belostotsky V; Atkinson SA; Filler G
    Can J Kidney Health Dis; 2024; 11():20543581241234723. PubMed ID: 38487751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
    Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.
    Lim K; Lu TS; Molostvov G; Lee C; Lam FT; Zehnder D; Hsiao LL
    Circulation; 2012 May; 125(18):2243-55. PubMed ID: 22492635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of fibroblast growth factor-23 are associated with muscle mass in haemodialysis patients.
    Fukasawa H; Ishigaki S; Kinoshita-Katahashi N; Niwa H; Yasuda H; Kumagai H; Furuya R
    Nephrology (Carlton); 2014 Dec; 19(12):784-90. PubMed ID: 25185859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.